Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations.
作者信息
Concha Josef Symon S, Patsatsi Aikaterini, Marshak-Rothstein Ann, Liu Ming-Lin, Sinha Animesh A, Lee Lela A, Merola Joseph F, Jabbari Ali, Gudjonsson Johann E, Chasset François, Jarrett Paul, Chong Benjamin, Arkin Lisa, Fernandez Anthony P, Caproni Marzia, Greenberg Steven A, Kim Hee Joo, Pearson David R, Femia Alisa, Vleugels Ruth Ann, Fiorentino David, Fujimoto Manabu, Wenzel Joerg, Werth Victoria P
机构信息
Corporal Michael J. Crescenz VAMC, Philadelphia, Pennsylvania, USA; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Division of Rheumatology, Department of Medicine, University of Massachusetts School of Medicine, Worcester, Massachusetts, USA.
出版信息
J Invest Dermatol. 2019 Feb;139(2):270-276. doi: 10.1016/j.jid.2018.08.017. Epub 2018 Sep 19.
Abstract
摘要
相似文献
1
Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations.
J Invest Dermatol. 2019 Feb;139(2):270-276. doi: 10.1016/j.jid.2018.08.017. Epub 2018 Sep 19.
2
Practice and Educational Gaps in Lupus, Dermatomyositis, and Morphea.
Dermatol Clin. 2016 Jul;34(3):243-50. doi: 10.1016/j.det.2016.02.006.
3
The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis.
J Am Acad Dermatol. 2017 Aug;77(2):374-377. doi: 10.1016/j.jaad.2017.03.027.
4
From pathogenesis, epidemiology, and genetics to definitions, diagnosis, and treatments of cutaneous lupus erythematosus and dermatomyositis: a report from the 3rd International Conference on Cutaneous Lupus Erythematosus (ICCLE) 2013.
J Invest Dermatol. 2015 Jan;135(1):7-12. doi: 10.1038/jid.2014.316.
5
Cutaneous Lupus Erythematosus and Dermatomyositis: Utilizing Assessment Tools for Treatment Efficacy.
J Invest Dermatol. 2022 Mar;142(3 Pt B):936-943. doi: 10.1016/j.jid.2021.09.036. Epub 2021 Dec 21.
6
Cutaneous manifestations of selected rheumatologic diseases.
Am Fam Physician. 1996 Apr;53(5):1625-36.
7
Adverse cutaneous reactions secondary to hydroxychloroquine in patients with dermatomyositis, lupus erythematosus, and lichen planopilaris.
J Am Acad Dermatol. 2021 Oct;85(4):1046-1047. doi: 10.1016/j.jaad.2021.02.034. Epub 2021 Feb 17.
8
[Cutaneous lupus erythematosus, a multidimensional entity].
Rev Med Inst Mex Seguro Soc. 2015 Nov-Dec;53(6):764-72.
9
Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.
Arch Dermatol. 2002 Sep;138(9):1231-3; discussion 1233. doi: 10.1001/archderm.138.9.1231.
10
Subacute cutaneous lupus erythematosus: a paraneoplastic dermatosis?
Clin Exp Dermatol. 2005 Nov;30(6):655-8. doi: 10.1111/j.1365-2230.2005.01900.x.
引用本文的文献
1
The Diagnostic Role of Skin Manifestations in Rheumatic Diseases in Children: A Critical Review of Paediatric Vasculitis.
Int J Mol Sci. 2024 Jul 3;25(13):7323. doi: 10.3390/ijms25137323.
2
International exchange on the clinical practice and research of rheumatic skin diseases: A report of the 5th International Conference of Cutaneous Lupus Erythematosus.
J Dermatol. 2024 Jul;51(7):881-884. doi: 10.1111/1346-8138.17153. Epub 2024 Mar 7.
3
Lymphedema of the Arm after COVID-19 Vaccination in a Patient with Hidden Breast Cancer and Paraneoplastic Dermatomyositis.
Vaccines (Basel). 2022 Jul 30;10(8):1219. doi: 10.3390/vaccines10081219.
4
Importance of collaboration of dermatology and rheumatology to advance the field for lupus and dermatomyositis.
Int J Womens Dermatol. 2021 Sep 24;7(5Part A):583-587. doi: 10.1016/j.ijwd.2021.09.002. eCollection 2021 Dec.
5
The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review.
Ann Transl Med. 2021 Mar;9(5):431. doi: 10.21037/atm-20-5048.
6
Cytotoxicity Evaluation of Chloroquine and Hydroxychloroquine in Multiple Cell Lines and Tissues by Dynamic Imaging System and Physiologically Based Pharmacokinetic Model.
Front Pharmacol. 2020 Nov 20;11:574720. doi: 10.3389/fphar.2020.574720. eCollection 2020.
7
Current Concepts and Future Approaches in the Treatment of Cutaneous Lupus Erythematosus: A Comprehensive Review.
Drugs. 2019 Jul;79(11):1199-1215. doi: 10.1007/s40265-019-01151-8.
8
A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus.
Br J Dermatol. 2019 May;180(5):964-965. doi: 10.1111/bjd.17344.
9
Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus.
F1000Res. 2019 Mar 25;8. doi: 10.12688/f1000research.17787.1. eCollection 2019.
本文引用的文献
1
Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists.
Br J Dermatol. 2019 Jan;180(1):165-171. doi: 10.1111/bjd.17012. Epub 2018 Oct 5.
2
Fas ligand promotes an inducible TLR-dependent model of cutaneous lupus-like inflammation.
J Clin Invest. 2018 Jul 2;128(7):2966-2978. doi: 10.1172/JCI98219. Epub 2018 Jun 11.
3
Classification of myositis.
Nat Rev Rheumatol. 2018 May;14(5):269-278. doi: 10.1038/nrrheum.2018.41. Epub 2018 Apr 12.
4
Itch in dermatomyositis: the role of increased skin interleukin-31.
Br J Dermatol. 2018 Sep;179(3):669-678. doi: 10.1111/bjd.16498. Epub 2018 Jun 21.
5
Applicability of EULAR/ACR classification criteria for dermatomyositis to amyopathic disease.
J Am Acad Dermatol. 2018 Jul;79(1):77-83.e1. doi: 10.1016/j.jaad.2017.12.055. Epub 2017 Dec 29.
6
2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups.
Arthritis Rheumatol. 2017 Dec;69(12):2271-2282. doi: 10.1002/art.40320. Epub 2017 Oct 27.
7
Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus.
J Investig Dermatol Symp Proc. 2017 Oct;18(2):S57-S63. doi: 10.1016/j.jisp.2016.11.001.
8
Development of classification criteria for discoid lupus erythematosus: Results of a Delphi exercise.
J Am Acad Dermatol. 2017 Aug;77(2):261-267. doi: 10.1016/j.jaad.2017.02.030. Epub 2017 Jun 9.
9
Immunostimulatory Endogenous Nucleic Acids Drive the Lesional Inflammation in Cutaneous Lupus Erythematosus.
J Invest Dermatol. 2017 Jul;137(7):1484-1492. doi: 10.1016/j.jid.2017.03.018. Epub 2017 Mar 27.
10
Predictors of low quality of life in patients with discoid lupus.
Br J Dermatol. 2017 Oct;177(4):e147-e149. doi: 10.1111/bjd.15490. Epub 2017 Sep 27.
Zotero 插件